| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,257 |
2,596 |
$612K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,782 |
4,425 |
$535K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
788 |
571 |
$217K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,032 |
973 |
$151K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
832 |
645 |
$107K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
608 |
519 |
$90K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,043 |
883 |
$60K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
363 |
274 |
$51K |
| 80053 |
Comprehensive metabolic panel |
3,936 |
3,266 |
$27K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
296 |
292 |
$25K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,740 |
3,077 |
$19K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
134 |
132 |
$19K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,426 |
830 |
$19K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
54 |
44 |
$10K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
89 |
77 |
$9K |
| 36415 |
Collection of venous blood by venipuncture |
3,937 |
3,239 |
$9K |
| 84443 |
Thyroid stimulating hormone (TSH) |
540 |
528 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
468 |
439 |
$6K |
| 70450 |
Computed tomography, head or brain; without contrast material |
167 |
155 |
$6K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
338 |
242 |
$6K |
| 84484 |
|
1,065 |
816 |
$5K |
| 81001 |
|
1,529 |
1,366 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
511 |
483 |
$4K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
27 |
27 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
13 |
13 |
$3K |
| 83690 |
|
417 |
374 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
469 |
412 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
29 |
28 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
457 |
394 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
26 |
24 |
$2K |
| 80061 |
Lipid panel |
223 |
221 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
154 |
136 |
$1K |
| 87077 |
|
171 |
153 |
$1K |
| 87186 |
|
156 |
140 |
$1K |
| 81025 |
|
115 |
108 |
$932.43 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
173 |
150 |
$825.98 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
177 |
175 |
$793.04 |
| 83605 |
|
128 |
101 |
$589.79 |
| 73630 |
|
47 |
40 |
$567.06 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
13 |
13 |
$495.45 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
12 |
12 |
$468.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
31 |
30 |
$424.17 |
| 85027 |
|
66 |
60 |
$266.23 |
| 85610 |
|
78 |
60 |
$242.97 |
| 84439 |
|
25 |
25 |
$232.16 |
| 73130 |
|
14 |
13 |
$188.72 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
13 |
13 |
$182.18 |
| 73610 |
|
12 |
12 |
$177.06 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
43 |
36 |
$146.11 |
| 11721 |
|
13 |
12 |
$142.67 |
| J2704 |
Injection, propofol, 10 mg |
13 |
13 |
$126.41 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14 |
14 |
$119.04 |
| 82150 |
|
18 |
17 |
$103.01 |
| 85007 |
|
41 |
39 |
$98.90 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
33 |
25 |
$45.43 |
| A9270 |
Non-covered item or service |
100 |
51 |
$0.00 |